1056 GMT - Alcon's third-quarter results were worse than expected and raise questions about the eyecare specialist's outlook for next year, Jefferies analysts say in a note. Investors had lower expectations for the third-quarter results, but the update was still worse than anticipated, the analysts say. Revenue missed consensus estimates and full-year guidance was mostly lowered at the midpoint of the new narrowed ranges, even if third-quarter earnings beat forecasts, they add. Competitive pressure that has weighed on sales of Alcon's implantable products could persist into the fourth quarter, Jefferies says. Zurich-listed shares fall 5.6%.